Therapeutic inhibition of the JAK-STAT pathway in the treatment of inflammatory bowel disease.

Chen, Zihan; Jiang, Ping; Su, Dan; Zhao, Yu; Zhang, Mingming

Chen, Zihan; Jiang, Ping; Su, Dan; Zhao, Yu; Zhang, Mingming.

Afiliación

Chen Z; School of Medicine, Shanghai Jiao Tong University, Shanghai 200001, China.
Jiang P; Department of Gastroenterology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing University, Nanjing 210093, China.
Su D; FUJIFILM Diosynth Biotechnologies, Watertown, 02472, MA, United States.
Zhao Y; University of Chicago, Pritzker School of Molecular Engineering, Chicago, IL, 60637.
Zhang M; School of Medicine, Shanghai Jiao Tong University, Shanghai 200001, China; Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, NHC Key Laboratory of Digestive Diseases, State Key Laboratory for Oncogenes and Related Genes, Renji Hospital, School of Medicine, Shangha

Cytokine Growth Factor Rev ; 79: 1-15, 2024 Oct.

Article en En | MEDLINE | ID: mdl-39179485

ABSTRACT

ABSTRACT

Inflammatory bowel disease (IBD) encompasses a group of non-specific chronic intestinal inflammatory conditions of unclear etiology. The current treatment and long-term management primarily involve biologics. Nevertheless, some patients experience treatment failure or intolerance to biologics [1], making these patients a primary focus of IBD research. The Janus kinase (JAK)-Signal Transducers and Activator of Transcription (STAT) signal transduction pathway is crucial to the regulation of immune and inflammatory responses [2], and plays an important role in the pathogenesis of IBD. JAK inhibitors alleviate IBD by suppressing the transmission of JAK-STAT signaling pathway. As the first small-molecule oral inhibitor for IBD, JAK inhibitors greatly improved the treatment of IBD and have demonstrated significant efficacy, with tofacitinib and upadacitinib being approved for the treatment of ulcerative colitis (UC) [3]. JAK inhibitors can effectively alleviate intestinal inflammation in IBD patients who have failed to receive biologics, which may bring new treatment opportunities for refractory IBD patients. This review aims to elucidate the crucial roles of JAK-STAT signal transduction pathway in IBD pathogenesis, examine its role in various cell types within IBD, and explore the research progress of JAK inhibitors as therapeutic agents, paving the road for new IBD treatment strategies.

Asunto(s)

Enfermedades Inflamatorias del Intestino; Inhibidores de las Cinasas Janus; Quinasas Janus; Factores de Transcripción STAT; Transducción de Señal; Humanos; Transducción de Señal/efectos de los fármacos; Factores de Transcripción STAT/metabolismo; Factores de Transcripción STAT/antagonistas & inhibidores; Quinasas Janus/antagonistas & inhibidores; Quinasas Janus/metabolismo; Enfermedades Inflamatorias del Intestino/tratamiento farmacológico; Inhibidores de las Cinasas Janus/uso terapéutico; Inhibidores de las Cinasas Janus/farmacología; Animales; Piperidinas/uso terapéutico; Piperidinas/farmacología; Pirimidinas/uso terapéutico; Pirimidinas/farmacología; Colitis Ulcerosa/tratamiento farmacológico; Compuestos Heterocíclicos con 3 Anillos

Palabras clave

Inflammatory bowel disease; JAK family; JAK inhibitors; JAK-STAT signaling pathway; STAT family

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Inflamatorias del Intestino / Transducción de Señal / Factores de Transcripción STAT / Quinasas Janus / Inhibidores de las Cinasas Janus Límite: Animals / Humans Idioma: En Revista: Cytokine Growth Factor Rev Asunto de la revista: ALERGIA E IMUNOLOGIA / BIOQUIMICA Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google